Artivion (NYSE:AORT) Trading Up 7% – Time to Buy?

Artivion, Inc. (NYSE:AORT)’s stock price shot up 7% during trading on Thursday . The company traded as high as $26.01 and last traded at $26.0150. 396,020 shares were traded during mid-day trading, a decline of 31% from the average session volume of 577,641 shares. The stock had previously closed at $24.31.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AORT shares. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings cut Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th. Citizens Jmp dropped their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Friday, April 10th. Finally, Stifel Nicolaus set a $45.00 price objective on Artivion in a research report on Monday, June 1st. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and an average target price of $44.17.

Artivion Stock Performance

The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The company’s fifty day moving average is $22.46 and its 200 day moving average is $33.03. The company has a market cap of $1.22 billion, a P/E ratio of 104.45 and a beta of 1.26.

Insider Activity

In other news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the transaction, the senior vice president owned 60,259 shares in the company, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Artivion

Institutional investors and hedge funds have recently bought and sold shares of the stock. Conestoga Capital Advisors LLC purchased a new stake in Artivion during the 1st quarter valued at $43,044,000. Summit Partners Public Asset Management LLC purchased a new position in shares of Artivion in the fourth quarter valued at about $39,401,000. Invesco Ltd. raised its stake in shares of Artivion by 211.9% during the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after acquiring an additional 748,119 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Artivion by 144.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock valued at $24,510,000 after acquiring an additional 317,518 shares during the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Artivion by 235.5% during the third quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after purchasing an additional 313,446 shares during the period. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.